The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms.

The article focuses on a case study that was conducted to determine whether CDKN1C methylation is a frequent event in myeloid leukemia and plasma cell neoplasms. Thirty-six multiple myeloma (MM) patients were included in the study. The Durie-Salmon staging system and the International Prognostic Index (IPI) were used for clinical and prognostic discrimination of patients. The study showed that CDKN1C methylation is not a frequent event in myeloid and plasma cell neoplasms.